Schizophrenia and related psychoses
Conditions
Interventions
Product Name: L-Lysine
Pharmaceutical Form: Powder for oral solution
Sponsors
Sahlgrenska Acadademy, GU
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Ten well-defined psychiatric outpatients will be recruited from the following two clinics: Psykosteamet Järntorget, and Psykosvård i Väster, at the Sahlgrenska University Hospital, Göteborg. All subjects are required to be on a stable dose of antipsychotic medication for at least three months prior to the start of the study. No major medical or neurological condition should be present as assessed by a comprehensive medical history and a medical examination. Further, all subjects are required to have normal admission laboratory tests and vital signs. Substance abuse, apart from smoking, will be grounds for exclusion. Prescribed medications including antipsychotic drugs will be allowed if the patient is on a stable dosing regimen. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: See E.3
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To investigate the use of L-lysine, an amino acid that interferes with the production of the signalling molecule, nitric oxide, as an adjunctive treatment for schizophreniform disorders.;Secondary Objective: ;Primary end point(s): Improvement in psychosis severity with emphasis on cognitive function is the primary end point and will be evaluated by appropriate neuropsychiatric tests before and after the treatment period. | — |
Countries
Sweden
Outcome results
None listed